MedTrace Logo

Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation

NCT05474664 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-12-03

No results posted yet for this study

Summary

This study is phase 2 open-label, single-arm, multi-center clinical trial to evaluate the efficacy and safety of Camostat mesylate in patients with Protein-losing enteropathy after Fontan operation.

Conditions

  • Fontan Operation
  • Protein-Losing Enteropathy
  • Camostat Mesylate

Interventions

DRUG

Camostat mesylate

1. 4\~12 years old: Camostate mesylate 100 mg, 2 times a day 2. greater than 13 years old: Camostate mesylate 100 mg, 3 times a day

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Gi Beom B Kim · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-03
Primary Completion
2024-07-12
Completion
2024-10-08

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05474664 on ClinicalTrials.gov